“Continuous Weekly Adalimumab is the Optimal Long-Term Strategy for Patients with Moderate-to-Severe Hidradenitis Suppurativa: Results from the PIONEER Open Label Extension Trial”, J of Skin, vol. 1, no. 3.1, p. s129, Oct. 2017.